AI assistant
AstraZeneca PLC Major Shareholding Notification 2025
5229_mrq_2025-08-28_7fb13d46-4e1d-4d1a-9086-84801504223a.html
Major Shareholding Notification
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 0696X
AstraZeneca PLC
28 August 2025
28 August 2025
On 27 August 2025, AstraZeneca PLC (the Company) was notified by The Capital Group Companies, Inc. (Capital Group) that the TR-1 notification it submitted to the Company on 25 August 2025, and which was subsequently announced by the Company on 26 August 2025 under RNS No. 6772W, was provided in error.
Accordingly, shareholders should disregard the TR-1 notification announced by the Company on 26 August 2025 and instead refer to the TR-1 notification in relation to Capital Group announced by the Company on 21 August 2025, which is available under RNS No. 2435W / at:
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .
Matthew Bowden
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLGCGDIISDDGUI